Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.65 |
| ▸ | CCR2 | P41597 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063312 | 0.95 | HSD11B1 (0.60) | HSD11B1CCR2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3066057 | 0.79 | HSD11B1 (1.00) | HSD11B1CCR2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12509445 | 0.77 | HSD11B1 (0.69) | HSD11B1OPRL1OPRM1OPRK1 | |
| SCHEMBL3050281 | 0.77 | HSD11B1 (1.00) | HSD11B1CCR2OPRL1OPRM1OPRK1 | |
| SCHEMBL13090626 | 0.76 | HSD11B1 (0.72) | HSD11B1CCR2OPRL1OPRM1OPRK1 | |
| SCHEMBL13845863 | 0.76 | HSD11B1 (0.69) | HSD11B1CCR2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3055381 | 0.74 | HSD11B1 (1.00) | HSD11B1CCR2OPRL1OPRM1OPRK1 | |
| SCHEMBL3070980 | 0.73 | HSD11B1 (0.77) | HSD11B1CCR2OPRL1OPRM1OPRK1 | |
| SCHEMBL2267177 | 0.73 | HSD11B1 (0.63) | HSD11B1OPRL1OPRM1OPRK1 | |
| SCHEMBL3061253 | 0.72 | HSD11B1 (0.78) | HSD11B1CCR2OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470849-B2 | 7-azaindole derivatives as selective 11-β-hydroxysteroid dehydrogenase type 1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-25 | — | — | US | claimed |
| EP-2247589-B1 | 7-AZAINDOLE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | MERCK PATENT GMBH (DE) | 2012-11-21 | — | — | EP | claimed |
| US-20100267761-A1 | 7-Azaindole Derivatives as Selective 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors | MERCK PATENT GESELLSCHAFT | 2010-10-21 | — | — | US | claimed |
| US-8470849-B2 | 7-azaindole derivatives as selective 11-β-hydroxysteroid dehydrogenase type 1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-2247589-B1 | 7-AZAINDOLE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | MERCK PATENT GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20100267761-A1 | 7-Azaindole Derivatives as Selective 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors | MERCK PATENT GESELLSCHAFT | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267761-A1 | 7-Azaindole Derivatives as Selective 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885CCR2 2876/4885CYP3A4 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.